Literature DB >> 6157479

Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells.

J B Baker, D A Low, R L Simmer, D D Cunningham.   

Abstract

This report identifies a component of normal human fibroblasts that forms a covalent linkage with thrombin and urokinase (urinary plasmingoen activator) and mediates most of the specific cellular binding of these proteases. This component, here named protease-nexin (PN), is both associated with the cell surface and released into the culture medium. In several ways PN resembles antithrombin III (AT3), a prominent inhibitor of thrombin in serum: PN links thrombin, probably via an ester bond; PN does not link thrombin blocked at its catalytic site serine; PN has a high-affinity heparin-binding site; and heparin greatly accelerates the rate of linkage between soluble PN and thrombin. Despite these similarities, PN and AT3 are distinct; they differ in size and are not immunologically cross-reactive. Whereas AT3 regulates the proteolytic activity of thrombin in serum, PN may regulates the activity of serine proteases at and near the cell surface.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6157479     DOI: 10.1016/0092-8674(80)90112-9

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  95 in total

Review 1.  Regulation of renal sodium handling through the interaction between serine proteases and serine protease inhibitors.

Authors:  Kenichiro Kitamura; Kimio Tomita
Journal:  Clin Exp Nephrol       Date:  2010-06-11       Impact factor: 2.801

2.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.

Authors:  I Bolon; M Devouassoux; C Robert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease.

Authors:  S L Wagner; J W Geddes; C W Cotman; A L Lau; D Gurwitz; P J Isackson; D D Cunningham
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

4.  Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  Sekiko Taneda; Kelly L Hudkins; Anja S Mühlfeld; Jolanta Kowalewska; Jeffrey W Pippin; Stuart J Shankland; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

5.  Serpine2 deficiency results in lung lymphocyte accumulation and bronchus-associated lymphoid tissue formation.

Authors:  Siva Kumar Solleti; Sorachai Srisuma; Soumyaroop Bhattacharya; Javier Rangel-Moreno; Kaiser M Bijli; Troy D Randall; Arshad Rahman; Thomas J Mariani
Journal:  FASEB J       Date:  2016-04-08       Impact factor: 5.191

6.  Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation.

Authors:  V L Turgeon; E D Lloyd; S Wang; B W Festoff; L J Houenou
Journal:  J Neurosci       Date:  1998-09-01       Impact factor: 6.167

7.  A coagulation pathway on bovine aortic segments leading to generation of Factor Xa and thrombin.

Authors:  D M Stern; P P Nawroth; W Kisiel; D Handley; M Drillings; J Bartos
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma.

Authors:  D Strehlow; A Jelaska; K Strehlow; J H Korn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

9.  SERPINE2 polymorphisms and chronic obstructive pulmonary disease.

Authors:  Seung Ick Cha; Hyo-Gyoung Kang; Jin Eun Choi; Min Jung Kim; Jaeho Park; Won Kee Lee; Chang Ho Kim; Tae Hoon Jung; Jae Yong Park
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

10.  Chronic obstructive pulmonary disease: towards pharmacogenetics.

Authors:  Alice M Wood; See Ling Tan; Robert A Stockley
Journal:  Genome Med       Date:  2009-11-30       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.